Searched for
SPECIALTY DRUG LAUNCH
These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...- From oncology to obesity, Pfizer bets big on India for its next growth wavePfizer is prioritizing India for future growth. The company plans to launch new medicines here soon after their global release. Pfizer aims...
- Eli Lilly brings monthly Alzheimer's therapy donanemab to India at ₹91,688 per vialEli Lilly is making Alzheimer's a major focus for its future innovations. The company is also expanding its specialty medicine offerings in...
- Alzheimer's a key part of Eli Lilly's India specialty medicine push, says company's country head Winselow TuckerEli Lilly has introduced Lormalzi in India, a pioneering treatment for Alzheimer's that specifically targets amyloid plaques, a significant...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Market bets on Aurobindo as Europe, US sales show uptickAurobindo Pharma stock is performing well. Sales in Europe are improving. New products are launching in the US. The company is also develop...
- Biocon rolls out two biosimilars in US marketBiocon has launched two new biosimilar medicines, Bosaya and Aukelso, in the United States. These drugs treat serious bone conditions. They...
- NATCO Pharma launches generic blood cancer treatment medicine in USNATCO Pharma has launched generic Pomalidomide capsules in the US. This drug treats blood and bone marrow cancer. It is a generic version o...
- Sun Pharma shines in US, home glow to help company beat industry showThe India business, accounting for a third of the company's total revenues, grew at 11%. This is a volume-led growth aided by new product l...
- Sun Pharma's hair loss drug in the cross hairs in USLeqselvi is used for the treatment of alopecia areata, an autoimmune disease that leads to hair loss, and was approved by the US Food and D...
- Time to buy pharma? 3 stocks Forum Parekh is betting onZydus Life's US business is going to report a good set of numbers. Also, in India, wellness products are doing good, Overall Zydus Life wil...
- Glenmark's partner Hikma launches specialty drug Ryaltris in USRyaltris is the only fixed-dose combination of olopatadine hydrochloride and mometasone furoate approved by the USFDA for the treatment of ...
- Does Sun Pharma's specialty portfolio hold key to its performance?According to the FY 2022 annual report of Sun Pharma, it is ranked number 1 in terms of prescriptions with an 8.34% market share in India. ...
- Sun Pharma might finally have a prescription for the specialty dreamThe ramp-up in its specialty business over the past year has increasingly turned skeptics into believers. The company has four major produc...
- ETIG Analysis: Five reasons why the pharma sector has been the biggest beneficiary of the pandemicThe events of the recent months prompted the government to roll out an incentive scheme to promote the local production of key active ingre...
- Is specialty business ‘a go or a no-go’ segment for pharma companies?Leading pharma companies invested in specialty business to create a long-term growth driver.
- Sun Pharma climbs 2% on USFDA approvalThe drug in question is CEQUA (cyclosporine ophthalmic solution) 0.09 per cent.
- Complex generics, biosimilars & specialty to be growth drivers: LupinWhile sustaining and growing its presence in the generics segment, Lupin is planning to invest heavily in developing high barrier products ...
- Sun Pharma launches first branded drug BromSite in USThe launch marks Sun Pharma’s entry into the branded drugs business in the US, a segment that many generic drug companies are targeting as ...
- Faster USFDA nod won't boost margins, will lead to intense competition: AnalystsIndian drug makers may be receiving an increasing number of approvals from the USFDA for drug launches in the United States.
Load More
